Abstracts Archive - Page 86 of 2607 - ACR Meeting Abstracts

Abstract Number: 0446 • ACR Convergence 2025
A Balancing Act: The Interplay Between Resilience and Frailty in Rheumatoid Arthritis
Hannah Brubeck¹, Kylie Riggles¹, Adrienne Tanus¹, Nadine El-ayache², George Mount², Elizabeth Wahl², Courtney Loecker³, Jose Garcia⁴, Dolores Shoback⁵, Joshua Baker⁶, Patti Katz⁷, Ariela Orkaby⁸ and Katherine Wysham⁹, ¹VA Puget Sound Health Care System, Seattle, WA, ²VA Puget Sound Health Care System & University of Washington, Seattle, WA, ³University of Nebraska Medical Center, Omaha, ⁴VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ⁵San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷UCSF, San Rafael, CA, ⁸VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA, ⁹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty, a state of decreased physiological reserve and heightened vulnerability to stressors, occurs prematurely in rheumatoid arthritis (RA) and is associated with poor health…
Abstract Number: 0252 • ACR Convergence 2025
Capillaroscopic Signatures in Autoimmune Rheumatic Diseases: Unveiling Patterns in Systemic Sclerosis, Polyautoimmunity, and PAH
María Paula Carrillo¹, Juan Esteban Bedoya-Loaiza¹, Claudia Ibáñez-Antequera¹, Laura Gallego¹, Alejandro Escobar¹, Adriana Rojas-Villarraga² and Jairo Cajamarca-Baron³, ¹Fundacion universitaria de ciencias de la salud, Bogota, Distrito Capital de Bogota, Colombia, ²Fundacion Universitaria de Ciencias de la salud, Bogotá, Distrito Capital de Bogota, Colombia, ³Fundacion universitaria de ciencia de la Salud, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Nailfold capillaroscopy is a fundamental tool in rheumatology for assessing capillary morphology, allowing the differentiation between primary and secondary Raynaud’s phenomenon, identifying risks associated…
Abstract Number: 0549 • ACR Convergence 2025
High Prevalence of Obstructive Sleep Apnea in Psoriatic Arthritis: A Polysomnography-Based Cross-Sectional Study
Suzan Attar¹, Siraj Walli², Yasser Bawazir³, Mohammad Mustafa⁴, Ayah Boudal⁵, Faris alhejailli², Ahmad Bamagoos² and Omar Kanbr², ¹King Abdulaziz University, Saudi Arabia, Jeddah, Saudi Arabia, ²KAU, Jeddah, Saudi Arabia, ³King Abdulaziz University, Jeddah, Saudi Arabia, ⁴Jeddah University, Jeddah, Saudi Arabia, ⁵King Abdullah Medical Complex, Jeddah, Saudi Arabia
Background/Purpose: Background: Obstructive sleep apnea (OSA) is increasingly recognized in patients with psoriatic arthritis (PsA), yet few studies have used polysomnography (PSG)—the gold-standard diagnostic method.…
Abstract Number: 0736 • ACR Convergence 2025
Effectiveness of Tocilizumab in strokes in patients with giant cell arteritis. Spanish multicenter study of clinical practice
Ana Serrano-Combarro¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, Javier Narváez⁵, Vicente Aldasoro Cáceres⁶, Rafael B. Melero-González⁷, Isabel De la Morena⁸, Ivan Ferraz Amaro⁹ and Ricardo Blanco¹⁰, ¹Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital León, LEON, Castilla y Leon, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁸HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA, VALENCIA, Spain, ⁹Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁰Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Stroke is a feared complication of giant cell arteritis (GCA). Tocilizumab (TCZ) has shown efficacy and safety in large-vessel vasculitis (LVV) including GCA. Our…
Abstract Number: 0730 • ACR Convergence 2025
Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
Victor Pimentel-Quiroz¹, Alvaro Oyarce-Calderón², Allison Figueroa-Sánchez³, Leonor León-Yaurimucha³, Rocío Gamboa-Cárdenas⁴, Zoila Rodríguez-Bellido⁵, Risto Perich-Campos⁶, Graciela Alarcón⁷ and Manuel Ugarte-Gil⁸, ¹Universidad Científica del Sur, San Isidro, Peru, ²Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Lima, Peru, ³Universidad Científica del Sur, Lima, Peru, ⁴Universidad Científica del Sur, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA, ⁸Universidad Cientifica del Sur, Lima, Peru
Background/Purpose: It is known that health-related quality of life (HRQoL) in patients with ANCA-associated vasculitis (AAV) is impaired. Categories of disease activity levels have been…
Abstract Number: 0745 • ACR Convergence 2025
Prevalence and Clinical Significance of Low ESR and CRP in Giant Cell Arteritis: A Population Based Study
Eugenio de Miguel, Natalia López-Juanes, Maria-Eugenia Miranda-Carus, Carlota Ureta, Chamaida Plasencia-Rodríguez and Irene Monjo Henry, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Traditionally, elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) had been considered a hallmark of GCA and both are included in the 2022…
Abstract Number: 0735 • ACR Convergence 2025
A Real-World Study from the Greater Paris Clinical Data Warehouse
Aïcha Kante¹, Olivier Hassanaly², Geoffroy Peyrac³, David Saadoun⁴, Cacoub Patrice⁴, Alexis REGENT⁵, Benjamin Terrier⁶, Luc Mouthon⁷, Arsène Mekinian⁸, Karim Sacré⁹, Jean-François Alexandra¹⁰, Sébastien Abad¹¹, Robin Dhote¹¹, Cécile goujard¹², Damien Sène¹³, Stéphane Mouly¹⁴, Baptiste Hervier¹⁵, Olivier Bory¹⁶, Elisabeth Aslangul¹⁶, Isabelle Mahé¹⁶, Anne Couvelard¹⁷, Yann Nguyen¹⁸, Agnès Lefort¹⁸, Sophie georgin-Lavialle¹⁹, Olivier Steichen¹⁹, Viet-Thi Tran²⁰ and Cloé Comarmond¹, ¹Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, INSERM U⁹⁴², Paris, France, ²Unité de recherche clinique, AP-HP, Hôpital Saint Louis, F⁷⁵⁰¹⁰, Paris, France, Paris, France, ³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁴Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ⁵Hopital Cochin, Paris, France, ⁶Cochin Hospital, Paris, France, ⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁸Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ⁹Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ¹⁰Internal Medicine, Hôpital Bichat, APHP, Paris, France, ¹¹Service de Médecine Interne, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP); Université Paris ¹³, Sorbonne Paris Cité, Bobigny, France, Bobigny, France, ¹²Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ¹⁴Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁵Internal Medicine Department, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France., Paris, France, ¹⁶Department of Internal Medicine, Louis-Mourier Hospital, AP-HP, Colombes, France, Colombes, France, ¹⁷Pathology Department, Bichat and Beaujon Hospitals, AP-HP, FHU MOSAIC, Université Paris Cité, Paris, France, Paris, France, ¹⁸Department of Internal Medicine, Beaujon Hospital, AP-HP Nord, Université Paris Cité, Clichy, France, Clichy, France, ¹⁹Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAe, Centre for Research in Epidemiology and Statistics (CRESS), Paris; and Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, AP-HP, Paris, France, Paris, France
Background/Purpose: Giant cell arteritis (GCA) relapses are frequent and often require therapeutic intensification in the form of glucocorticoids (GC) increase. GCA management has significantly evolved…
Abstract Number: 0758 • ACR Convergence 2025
Association Between Baseline IL-6 Levels and the Clinical Phenotype of Giant Cell Arteritis
Raquel Ugena-García¹, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Francina salabert-Carreras², Cristina Calomarde-Gómez¹, Cristina Rocamora-Gisbert³, Irene Peralta-García⁴, Niccolo Viveros², Anne Riveros Frutos³, Ivette Casafont-Solé¹ and Judit Font-Urgelles¹, ¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna. Karolinska University Hospital, Medical Unit of Gastroenterology, Dermatology, Rheumatology. Theme Inflammation and Ageing, Stockholm, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in patients over the age of 50. Interleukin-6 (IL-6) has been shown to…
Abstract Number: 0773 • ACR Convergence 2025
Clinical Significance of Anti-MDA5 Epitope Antibodies as Prognostic Indicators for Interstitial Lung Disease With or Without Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima², Motohiro Nonaka³, Norimichi Nomura⁴, Atsubumi Ogawa¹, Yasuhiro Nohda¹, Mirei Shirakashi², Ryosuke Hiwa¹, Hideaki Tsuji¹, Hajime Yoshifuji², Shogo Matsuda⁵, Masao Katsushima⁶, Michinori Ishitoku⁷, Yusuke Yoshida⁷, Yasuyuki Todoroki⁸, Satoshi Kubo⁹, Tomohiro Handa¹⁰, Hiromi Tomioka¹¹, Ryo Tachikawa¹², Keisuke Tomii¹², Kiminobu Tanizawa¹³, Toru Arai¹⁴, Takuya Kotani¹⁵, Motomu Hashimoto¹⁶, Shintaro Hirata⁷, Yoshiya Tanaka¹⁷, Tsuneyo Mimori¹⁸ and Akio Morinobu¹⁹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan, ³Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Internal Medicine IV, Division of Rheumatology, Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁶Department of Clinical Immunology, Osaka Metropolitan Graduate School of Medicine, Osaka, Japan, ⁷Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ⁸Department of Molecular Targeted Therapies, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Department of Molecular Targeted Therapies (DMTT), University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁰Department of Advanced Medicine for Respiratory Failure and Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹¹Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, Japan, ¹²Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan, ¹³Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Japan, ¹⁴Clinical Research Center, NHO Kinki-Chuo Chest Medical Center, Sakai, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical and Pharmaceutical University, Osaka, Japan, ¹⁶Osaka Metropolitan University, Osaka, Japan, ¹⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ¹⁸Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ¹⁹Kyoto University, Kyoto, Kyoto, Japan
Background/Purpose: Melanoma differentiation-associated gene 5 (MDA5) is a cytoplasmic RNA sensor and activates the innate immune response. Autoantibodies against MDA5 are associated with rapidly progressive…
Abstract Number: 0764 • ACR Convergence 2025
Frequency of large vessel vasculitis in giant cell arteritis with and without adventiitis of temporal artery – Is the presence of temporal arteritis sufficient to diagnose giant cell arteritis?-
Yoichiro Akiyama, Jun Nakamura, Ayako Kokuzawa, Hiroi Kusaka, Sho Tani, Fuminori Taniguchi, Kohei Morikawa, Haruka Kondo, Shotaro Yamamoto, Yasuyuki Kamata and Kojiro Sato, Jichi Medical University, Shimotsuke, Tochigi, Japan
Background/Purpose: Takayasu arteritis (TAK) and giant cell arteritis (GCA) belong to the large vessel vasculitis group. Differences between the two diseases have been reported based…
Abstract Number: 0739 • ACR Convergence 2025
Tocilizumab in Giant Cell Arteritis with ischemic vs non-ischemic manifestations
Carmen Secada-Gómez¹, Javier Loricera², Clara Moriano³, Santos Castañeda⁴, Javier Narváez⁵, Vicente Aldasoro Cáceres⁶, Olga Maiz⁷, Rafael B. Melero-González⁸, Paloma Vela Casasempere⁹, Susana Romero-Yuste¹⁰, Jose Luis Callejas¹¹, Eugenio de Miguel¹², Eva Galíndez Agirregoikoa¹³, Francisca Sivera¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez Martín¹⁶ and Ricardo Blanco¹, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital León, LEON, Castilla y Leon, Spain, ⁴Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷Hospital Universitario de Donosti, Donostia, Spain, ⁸COMPLEXO HOSPITALARIO UNIVERSITARIO DE OURENSE, O Carballino, Spain, ⁹Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁰University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁴Hospital General Universitario Elda, Elda, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Hospital Universitario ¹² de Octubre, Madrid, Spain
Background/Purpose: Tocilizumab (TCZ) is the only approved biological drug in the treatment of giant cell arteritis (GCA). However, there are no comparative studies on the…
Abstract Number: 0751 • ACR Convergence 2025
Impact of Treatment with Upadacitinib on Biomarkers Identified by Proteomics in Giant Cell Arteritis
Lisa Christ¹, Shalina Taylor², Yilin Xu², Rhiya Sharma², Thierry Sornasse², Yingtao Bi², Heath Guay², Arathi Setty³, Ana Romero⁴, Peter Merkel⁵, Eugenio de Miguel⁶, Christian Dejaco⁷ and Cornelia Weyand⁸, ¹Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Bern, Switzerland, ²AbbVie Inc, North Chicago, ³AbbVie Inc, North Chicago, IL, ⁴AbbVie, Barcelona, Spain, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Hospital Universitario La Paz, Madrid, Spain, ⁷Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ⁸Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester
Background/Purpose: Interleukin-6 (IL-6) and interferon-gamma (IFNγ) have been identified as key drivers in the pathogenesis of giant cell arteritis (GCA), that promote disease progression. The…
Abstract Number: 0544 • ACR Convergence 2025
Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort
Olivier Fakih¹, Anna Molto², Frank Verhoeven¹, Clément Prati¹ and WENDLING Daniel¹, ¹CHU de Besançon, Besançon, Franche-Comte, France, ²Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Despite a choice of multiple targeted DMARDs, with different modes of action (MoA), a number of patients with axial spondyloarthritis (axSpA) have failed several…
Abstract Number: 0762 • ACR Convergence 2025
Relapse rate, predictors of relapses and impact of introduction of interleukin-6-receptor inhibition on relapse rate in GCA- Data from the large REATS cohort from six vasculitis centers
Verena Schoenau¹, Giulia Corte², Koray Tascilar³, Fabian Hartmann², Sebastian Ott², Wolfgang Schmidt⁴, Andreas Krause⁵, Pfeil Alexander⁶, Peter Oelzner⁶, Marc Schmalzing⁷, Matthias Fröhlich⁸, Michael Gernert⁸, Jörg Henes⁹, Nils Venhoff¹⁰, Bernhard Hellmich¹¹, Bernhard Manger², Georg Schett¹² and Juergen Rech¹², ¹- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ²- Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch; Waldfriede Hospital, Rheumatology, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁶Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, ⁷Department of Medicine II, Rheumatology/ Immunology,University Hospital of Wuerzburg, Wuerzburg, Bayern, Germany, ⁸University Hospital of Wuerzburg, Department of Medicine II, Rheumatology/ Immunology, Wuerzburg, Germany, ⁹Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, ¹⁰University of Freiburg, Freiburg, Germany, ¹¹Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ¹²Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: The diagnosis and management of giant cell arteritis (GCA) has significantly evolved over the last decades, mainly due to advances in imaging techniques and…
Abstract Number: 0765 • ACR Convergence 2025
Rural Access to Physical Therapy for Osteoarthritis Rehabilitation (RAPTOR): A Pilot Feasibility Study
Allyn Bove, Emma Zavacky, Hallie Zeleznik, Christopher Bise, Charity Patterson, Bambang Parmanto and G Kelley Fitzgerald, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Individuals who live in rural areas are more likely to experience knee osteoarthritis-related disability and less likely to be referred to physical therapy for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].